Technische Universität München Klinikum rechts der Isar
Welcome,         Profile    Billing    Logout  
 5 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lorenzen, Sylvie
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Folinic acid, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Folinic acid, Oxaliplatin, 5-FU, Irinotecan, FOLFIRI, Folinic acid, 5-FU, CAPOX, Capecitaine, Oxaliplatin
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
RAMIRIS, NCT03081143 / 2015-005171-24: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

Active, not recruiting
2/3
429
Europe
FOLFIRI, Ramucirumab, Paclitaxel
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Gastric or EGJ Cancer
12/25
12/25
PRESTO, NCT05713838: Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Recruiting
2
32
Europe
Durvalumab, IMFINZI, FLOT, mFOLFOX-6, Radiotherapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Esophagus Adenocarcinoma
12/25
12/28
NCT06680622: Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Not yet recruiting
2
126
Europe
bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Amgen, Johannes Gutenberg University Mainz, Technical University of Munich
Metastatic Gastro-esophageal Adenocarcinoma
09/27
03/28
FUTURE, NCT06722183: Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Not yet recruiting
2
33
Europe
Futibatinib orally administered, Tislelizumab (i.v. 200mg)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler
Colorectal Cancer
06/27
06/27
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
NA
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
NCT06123468: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Active, not recruiting
1/2
56
Europe
Sacituzumab govitecan, Trodelvy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Gilead Sciences
Esophagogastric Adenocarcinoma
02/27
03/27
NCT03927573: Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker

Terminated
1
23
Europe
GEM3PSCA
AvenCell Europe GmbH, GCP-Service International Ltd. & Co. KG
Non-small Cell Lung Cancer, Prostate Cancer, Renal Cancer, Transitional Cell Carcinoma
06/23
06/23
SAPHIR, NCT04290806: Registry Platform Gastric/Esophageal Cancer

Recruiting
N/A
900
Europe
Routine care as per site standard
iOMEDICO AG
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
12/24
12/24

Download Options